<DOC>
	<DOCNO>NCT01204112</DOCNO>
	<brief_summary>The current study design estimate effect rifampin ( 600 mg orally every 24 hour 7 day ) pharmacokinetics single 30 mg dose ( CP-690,550 ) normal healthy volunteer</brief_summary>
	<brief_title>Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy male and/or female subject ( nonchildbearing potential ) Clinically significant disease condition Recent serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Tasocitinib ( CP-690</keyword>
	<keyword>550 )</keyword>
	<keyword>Rifampin</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>